Trillium Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics

TRIL 20.36

+2.0%

Nov 26 2:56 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

A.J. Mullen

To: scaram(o)uche who wrote (173)	4/5/2018 7:33:22 PM
From: tuck	1 Recommendation Read Replies (1) of 294

List of CD47 programs by an unknown Trillium long, with some reasonably balanced analysis. CD47 Players It notes that the Surface Oncology mAb actually does bind to RBCs, but spares them. The problem with that - and other similar approaches - is that to spare them, they use a weak effector, which means efficacy will be poor. It suggests the main threats will be from bispecifics such as Novimmune's, Shattuck's, and Hummingbird's, as well as Aurigene's oral peptide (for which I can find no IP whatsoever). Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next